Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) EBT (2016 - 2025)

Traws Pharma (TRAW) has disclosed EBT for 14 consecutive years, with -$4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 52.5% to -$4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$141.2 million, a 0.24% change, with the full-year FY2024 number at -$142.4 million, down 601.42% from a year prior.
  • EBT was -$4.1 million for Q3 2025 at Traws Pharma, up from -$5.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.8 million in Q4 2021 to a low of -$123.3 million in Q2 2024.
  • A 5-year average of -$11.9 million and a median of -$4.6 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 2575.66% in 2024, then skyrocketed 52.5% in 2025.
  • Traws Pharma's EBT stood at -$3.8 million in 2021, then crashed by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then decreased by 18.29% to -$5.3 million in 2024, then rose by 23.17% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's EBT are -$4.1 million (Q3 2025), -$5.3 million (Q4 2024), and -$8.5 million (Q3 2024).